Therefore, the targeting of key metabolic hubs (such as mTOR and HIF-1α) to restore the function of anti-inflammatory iTregs could be beneficial for targeted immuno- metabolic therapy in IBD (86). Here, HIF1A is linked to inflammatory bowel disease.